News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
727,688 Results
Type
Article (75305)
Company Profile (339)
Press Release (652044)
Multimedia
Podcasts (107)
Webinars (14)
Section
Business (192665)
Career Advice (3275)
Deals (36040)
Drug Delivery (128)
Drug Development (86243)
Employer Resources (182)
FDA (16792)
Job Trends (15728)
News (341841)
Policy (34937)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (6)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (6)
2024 Genetown Digital (7)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (12)
2024 Pharm Country Digital (8)
2024 Pharm Country Standard (5)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2967)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (90)
Alliances (49139)
ALS (98)
Alzheimer's disease (1487)
Antibody-drug conjugate (ADC) (149)
Approvals (16753)
Artificial intelligence (281)
Autoimmune disease (28)
Automation (15)
Bankruptcy (351)
Best Places to Work (12159)
BIOSECURE Act (21)
Biosimilars (118)
Biotechnology (234)
Bladder cancer (70)
Brain cancer (30)
Breast cancer (290)
Cancer (2283)
Cardiovascular disease (198)
Career advice (2774)
Career pathing (34)
CAR-T (166)
Cell therapy (450)
Cervical cancer (21)
Clinical research (69708)
Collaboration (876)
Compensation (532)
Complete response letters (30)
COVID-19 (2845)
CRISPR (44)
C-suite (252)
Cystic fibrosis (105)
Data (2139)
Decentralized trials (2)
Denatured (32)
Depression (53)
Diabetes (288)
Diagnostics (6620)
Digital health (19)
Diversity (9)
Diversity, equity & inclusion (43)
Drug discovery (127)
Drug pricing (122)
Drug shortages (33)
Duchenne muscular dystrophy (98)
Earnings (73231)
Editorial (43)
Employer branding (25)
Employer resources (158)
Events (105655)
Executive appointments (747)
FDA (18048)
Featured Employer (56)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (788)
Gene editing (113)
Generative AI (26)
Gene therapy (330)
GLP-1 (838)
Government (4973)
Grass and pollen (6)
Guidances (51)
Healthcare (20260)
Huntington's disease (25)
IgA nephropathy (28)
Immunology and inflammation (142)
Indications (29)
Infectious disease (3001)
Inflammatory bowel disease (149)
Inflation Reduction Act (10)
Influenza (54)
Intellectual property (97)
Interviews (618)
IPO (17015)
IRA (50)
Job creations (4005)
Job search strategy (2287)
Kidney cancer (11)
Labor market (35)
Layoffs (539)
Leadership (22)
Legal (8367)
Liver cancer (76)
Lung cancer (333)
Lymphoma (151)
Machine learning (5)
Management (63)
Manufacturing (325)
MASH (72)
Medical device (14007)
Medtech (14012)
Mergers & acquisitions (19598)
Metabolic disorders (763)
Multiple sclerosis (84)
NASH (23)
Neurodegenerative disease (104)
Neuropsychiatric disorders (34)
Neuroscience (2064)
NextGen: Class of 2025 (7276)
Non-profit (4978)
Northern California (2584)
Now hiring (36)
Obesity (414)
Opinion (273)
Ovarian cancer (76)
Pain (93)
Pancreatic cancer (83)
Parkinson's disease (157)
Partnered (23)
Patents (242)
Patient recruitment (108)
Peanut (51)
People (57767)
Pharmaceutical (78)
Pharmacy benefit managers (21)
Phase I (21380)
Phase II (30392)
Phase III (23033)
Pipeline (1175)
Policy (160)
Postmarket research (3198)
Preclinical (9347)
Press Release (69)
Prostate cancer (103)
Psychedelics (38)
Radiopharmaceuticals (262)
Rare diseases (417)
Real estate (6222)
Recruiting (73)
Regulatory (23838)
Reports (42)
Research institute (2604)
Resumes & cover letters (521)
Rett syndrome (4)
RNA editing (4)
RSV (50)
Schizophrenia (78)
Series A (140)
Series B (88)
Service/supplier (17)
Sickle cell disease (57)
Southern California (2212)
Special edition (18)
Spinal muscular atrophy (163)
Sponsored (34)
Startups (3891)
State (2)
Stomach cancer (15)
Supply chain (74)
Tariffs (34)
The Weekly (73)
United States (22751)
Vaccines (789)
Venture capitalists (42)
Weight loss (296)
Women's health (38)
Worklife (19)
Date
Today (182)
Last 7 days (545)
Last 30 days (2582)
Last 365 days (34022)
2025 (10094)
2024 (36466)
2023 (41337)
2022 (52545)
2021 (57194)
2020 (56014)
2019 (49795)
2018 (37907)
2017 (34954)
2016 (34365)
2015 (39518)
2014 (31715)
2013 (30585)
2012 (29650)
2011 (29971)
2010 (28523)
Location
Africa (1044)
Alabama (52)
Alaska (7)
Arizona (180)
Arkansas (14)
Asia (43777)
Australia (7767)
California (5916)
Canada (1951)
China (535)
Colorado (267)
Connecticut (278)
Delaware (143)
Europe (102121)
Florida (881)
Georgia (196)
Hawaii (1)
Idaho (63)
Illinois (557)
India (27)
Indiana (312)
Iowa (9)
Japan (161)
Kansas (107)
Kentucky (24)
Louisiana (13)
Maine (62)
Maryland (894)
Massachusetts (4457)
Michigan (221)
Minnesota (386)
Mississippi (2)
Missouri (91)
Montana (31)
Nebraska (24)
Nevada (62)
New Hampshire (68)
New Jersey (1698)
New Mexico (31)
New York (1700)
North Carolina (1064)
North Dakota (8)
Northern California (2584)
Ohio (207)
Oklahoma (15)
Oregon (37)
Pennsylvania (1342)
Puerto Rico (11)
Rhode Island (35)
South America (1395)
South Carolina (21)
South Dakota (1)
Southern California (2212)
Tennessee (102)
Texas (907)
Utah (177)
Virginia (155)
Washington D.C. (68)
Washington State (561)
West Virginia (3)
Wisconsin (51)
727,688 Results for "dong a st".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dong-A ST Secures European Approval for Stelara Biosimilar IMULDOSA
December 19, 2024
·
1 min read
Business
Shaperon and Dong-A ST Sign MOU for Nanobody-Based New Drug Development
Hudson Therapeutics announced that Shaperon, an innovative biopharmaceutical company specializing in immune therapeutics, has signed a Memorandum of Understanding with Dong-A ST for the development of nanobody-based new drugs.
June 10, 2024
·
4 min read
Press Releases
CHMP Recommends the Approval of Dong-A ST’s IMULDOSA, a Biosimilar to Stelara®
October 21, 2024
·
2 min read
FDA
US FDA Approves Dong-A ST’s IMULDOSA™ (ustekinumab-srlf), a Biosimilar to STELARA®
October 11, 2024
·
1 min read
FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara® (Ustekinumab)
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced that Accord BioPharma, Inc., a subsidiary of Intas Pharmaceuticals Ltd, in the United States has received a notification that the US Food and Drug Administration (“FDA”) has accepted its Biologics License Application (BLA) for DMB-3115, a proposed biosimilar to Stelara® (Ustekinumab), for substantive review.
January 5, 2024
·
2 min read
EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar
Dong-A ST (President/CEO Min-young Kim, KRX:170900) announced on July 14 that the European Medicine Agency (EMA) confirmed acceptance of Marketing Authorization Application (MAA) for DMB-3115, a biosimilar of Stelara ® (Ustekinumab).
July 17, 2023
·
2 min read
Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III
Dong-A ST (President and CEO: Min-young Kim) (KRX:170900) announced on January 16th that therapeutic equivalence and safety were established between DMB-3115 and Stelara, the reference drug, in global phase III.
January 17, 2023
·
3 min read
Business
Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer
Electra Therapeutics, Inc. today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.
December 11, 2023
·
4 min read
Genetown
NeuroBo Pharmaceuticals, Inc. and Dong-A ST Co. Ltd. Announce Strategic Collaboration to License and Develop Portfolio of Dong-A’s Cardio-Metabolic Therapies
NeuroBo Pharmaceuticals, Inc. (“NeuroBo”) (Nasdaq: NRBO), and Dong-A ST Co., Ltd. (“Dong-A”) (KOSE: A000640) today announced that they have entered into a conditional exclusive license agreement for NeuroBo to develop and commercialize DA-1241 and DA-1726.
September 15, 2022
·
9 min read
Business
Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration
Dong-A ST Co., Ltd., a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, announced that they have mutually agreed to terminate their collaboration and licensing agreement.
September 6, 2022
·
3 min read
1 of 72,769
Next
